CY1122494T1 - Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων - Google Patents
Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτωνInfo
- Publication number
- CY1122494T1 CY1122494T1 CY20191101303T CY191101303T CY1122494T1 CY 1122494 T1 CY1122494 T1 CY 1122494T1 CY 20191101303 T CY20191101303 T CY 20191101303T CY 191101303 T CY191101303 T CY 191101303T CY 1122494 T1 CY1122494 T1 CY 1122494T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fusion proteins
- polypeptide
- binding protein
- il15ra
- interleukin
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000003812 Interleukin-15 Human genes 0.000 title abstract 2
- 108090000172 Interleukin-15 Proteins 0.000 title abstract 2
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 title 1
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157911.7A EP3064507A1 (en) | 2015-03-06 | 2015-03-06 | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| PCT/EP2016/054729 WO2016142314A1 (en) | 2015-03-06 | 2016-03-07 | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122494T1 true CY1122494T1 (el) | 2021-01-27 |
Family
ID=52629425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101303T CY1122494T1 (el) | 2015-03-06 | 2019-12-11 | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10906952B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3064507A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6757338B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107636015A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017018975A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2978808A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1122494T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3265478T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2763598T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20192190T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE047818T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3265478T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3265478T (cg-RX-API-DMAC7.html) |
| RS (1) | RS59658B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3265478T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016142314A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| CN106380521B (zh) | 2015-07-02 | 2020-12-29 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| EP3430058A4 (en) | 2016-03-15 | 2019-10-23 | Generon (Shanghai) Corporation Ltd. | MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF |
| AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| PE20240950A1 (es) * | 2016-10-14 | 2024-05-06 | Xencor Inc | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117384929A (zh) | 2017-03-27 | 2024-01-12 | 新加坡国立大学 | 一种编码由细胞表达的嵌合受体的多核苷酸 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| UA125700C2 (uk) | 2017-04-03 | 2022-05-18 | Ф. Хоффманн-Ля Рош Аг | Імунокон'югати антитіла до pd-1 з мутантом il-2 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| KR20250056192A (ko) | 2017-08-07 | 2025-04-25 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME |
| CA3076014A1 (en) * | 2017-09-29 | 2019-04-04 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| TWI834636B (zh) * | 2018-02-26 | 2024-03-11 | 美商欣爍克斯公司 | Il-15結合物及其用途 |
| PE20201342A1 (es) * | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
| IL278090B2 (en) | 2018-04-18 | 2024-07-01 | Xencor Inc | Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof |
| WO2019246142A1 (en) * | 2018-06-18 | 2019-12-26 | Haiming Chen | Soluble bispecific fusion proteins for cancer immunotherapy |
| CN112368015B (zh) * | 2018-06-18 | 2025-04-29 | 安维达生物科技公司 | 细胞因子融合蛋白及其用途 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3847196A4 (en) * | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| CN109207430A (zh) * | 2018-09-25 | 2019-01-15 | 华东师范大学 | 一种嵌合抗原受体nk细胞及其制备方法和应用 |
| JP6935383B2 (ja) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
| KR20250154552A (ko) | 2018-09-27 | 2025-10-28 | 실리오 디벨럽먼트, 인크. | 마스킹된 사이토카인 폴리펩타이드 |
| MA53862A (fr) | 2018-10-12 | 2022-01-19 | Xencor Inc | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| CN114286683B (zh) * | 2019-07-17 | 2024-10-01 | 新加坡国立大学 | 由免疫细胞合成和分泌的功能性结合物 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN111690068B (zh) * | 2019-11-13 | 2022-04-19 | 中国科学技术大学 | 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用 |
| EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| CN114761433B (zh) * | 2019-12-11 | 2025-07-29 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
| CN116406380A (zh) * | 2020-09-17 | 2023-07-07 | 上海霖羲致企业管理有限公司 | 双特异性重组蛋白及其用途 |
| AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| KR20230113581A (ko) | 2020-11-25 | 2023-07-31 | 실리오 디벨럽먼트, 인크. | 종양 특이적 절단성 링커 |
| CN117186227A (zh) * | 2020-12-23 | 2023-12-08 | 瑞泽恩制药公司 | 编码锚修饰的抗体的核酸以及其用途 |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| WO2023280287A1 (en) * | 2021-07-09 | 2023-01-12 | Nanjing Legend Biotech Co., Ltd. | Interleukin-15 variants and uses thereof |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| CN113956346B (zh) * | 2021-10-26 | 2024-03-01 | 西安龙腾景云生物科技有限公司 | 一种重组白介素-15变体 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| WO2024085166A1 (ja) * | 2022-10-19 | 2024-04-25 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| CN120693344A (zh) * | 2023-02-14 | 2025-09-23 | 德国癌症研究公共权益基金会 | 具有改善的特性的il-15融合蛋白 |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2025147512A1 (en) * | 2024-01-02 | 2025-07-10 | Eli Lilly And Company | Immunogenicity assessment platform for biotherapeutic proteins |
| WO2025222129A2 (en) * | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| ATE516305T1 (de) * | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| MX2007006832A (es) | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Arreglos de antigeno interleucina 15 y usos de los mismos. |
| MX2009001203A (es) | 2006-08-01 | 2009-06-01 | Pieris Ag | Muteinas de lipocalina lacrimosa y metodos para obtener las mismas. |
| JP5501222B2 (ja) * | 2007-05-11 | 2014-05-21 | アルター・バイオサイエンス・コーポレーション | 融合分子及びｉｌ−１５変異体 |
| US20120196310A1 (en) | 2009-10-02 | 2012-08-02 | Christiane Jaeger | A-fucosylation detection in antibodies |
| DK2990798T3 (da) | 2009-12-07 | 2019-12-02 | Pieris Pharmaceuticals Gmbh | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål |
| EP2918607B1 (en) | 2010-09-21 | 2017-11-08 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| CA2859767C (en) | 2011-12-19 | 2018-09-11 | Synimmune Gmbh | Bispecific antibody molecule and use thereof for treatment of proliferative disease |
| US10202433B2 (en) | 2013-06-27 | 2019-02-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| PE20201342A1 (es) | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
-
2015
- 2015-03-06 EP EP15157911.7A patent/EP3064507A1/en not_active Withdrawn
-
2016
- 2016-03-07 CN CN201680025275.8A patent/CN107636015A/zh active Pending
- 2016-03-07 HU HUE16708154A patent/HUE047818T2/hu unknown
- 2016-03-07 PL PL16708154T patent/PL3265478T3/pl unknown
- 2016-03-07 HR HRP20192190TT patent/HRP20192190T1/hr unknown
- 2016-03-07 PT PT167081546T patent/PT3265478T/pt unknown
- 2016-03-07 CA CA2978808A patent/CA2978808A1/en active Pending
- 2016-03-07 JP JP2017564951A patent/JP6757338B2/ja not_active Expired - Fee Related
- 2016-03-07 SI SI201630550T patent/SI3265478T1/sl unknown
- 2016-03-07 WO PCT/EP2016/054729 patent/WO2016142314A1/en not_active Ceased
- 2016-03-07 EP EP16708154.6A patent/EP3265478B1/en not_active Revoked
- 2016-03-07 DK DK16708154.6T patent/DK3265478T3/da active
- 2016-03-07 RS RS20191593A patent/RS59658B1/sr unknown
- 2016-03-07 ES ES16708154T patent/ES2763598T3/es active Active
- 2016-03-07 US US15/556,282 patent/US10906952B2/en not_active Expired - Fee Related
- 2016-03-07 BR BR112017018975-5A patent/BR112017018975A2/pt not_active Application Discontinuation
-
2019
- 2019-12-11 CY CY20191101303T patent/CY1122494T1/el unknown
-
2020
- 2020-12-22 US US17/130,975 patent/US20210163564A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/565,942 patent/US20220324931A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6757338B2 (ja) | 2020-09-16 |
| RS59658B1 (sr) | 2020-01-31 |
| PL3265478T3 (pl) | 2020-03-31 |
| DK3265478T3 (da) | 2019-12-16 |
| HRP20192190T1 (hr) | 2020-02-21 |
| PT3265478T (pt) | 2020-01-08 |
| US20210163564A1 (en) | 2021-06-03 |
| SI3265478T1 (sl) | 2020-01-31 |
| ES2763598T3 (es) | 2020-05-29 |
| US20220324931A1 (en) | 2022-10-13 |
| US20180044391A1 (en) | 2018-02-15 |
| HUE047818T2 (hu) | 2020-05-28 |
| WO2016142314A1 (en) | 2016-09-15 |
| CA2978808A1 (en) | 2016-09-15 |
| US10906952B2 (en) | 2021-02-02 |
| EP3265478B1 (en) | 2019-09-11 |
| BR112017018975A2 (pt) | 2018-04-17 |
| CN107636015A (zh) | 2018-01-26 |
| JP2018512168A (ja) | 2018-05-17 |
| EP3265478A1 (en) | 2018-01-10 |
| EP3064507A1 (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| CY1125241T1 (el) | Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους | |
| CY1124806T1 (el) | Αντισωματα enanti-cd40 και χρησεις αυτων | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CY1123642T1 (el) | Αντισωματα enanti-pd-1 | |
| CY1124453T1 (el) | Πολυπεπτιδια που περιεχουν επικρατειες προσδεσης de novo και χρησεις αυτων | |
| CY1123925T1 (el) | Μια νεα μορφη il33, μεταλλαγμενες μορφες της il33, αντισωματα, δοκιμασιες και μεθοδοι χρησης των ιδιων | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| CY1121891T1 (el) | Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας | |
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| PH12018500252A1 (en) | Factor ix fusion protiens and methods of making and using same | |
| MX2022006760A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| CY1123274T1 (el) | Αντισωματα εναντι-οχ40 και χρησεις αυτων | |
| PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| CY1117162T1 (el) | Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης | |
| MX374811B (es) | Anticuerpos anti-tau y métodos de uso. | |
| CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| EA201791562A1 (ru) | Антигены цитомегаловируса и их применения | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
| MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. |